Attachment
Gates Package, p.250 · gates:exh:00143
Page text: p.250 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership
National Institute of Allergy and Infectious Diseases, NIH
Sheri Hild, Ph.D.
Program Director for National Primate Research Centers
Office of Research Infrastructure Programs, NIH
Samantha Jonson, M.P.S.
Special Assistant to the Director
National Center for Advancing Translational Sciences, NIH
Isis Kanevsky, Ph.D.
Director
Pfizer
Kent Lloyd, D.V.M., Ph.D.
Professor, Department of Surgery, School of Medicine
Director, Mouse Biology Program
Associate Director, Comprehensive Cancer Center
University of California, Davis Health
Joanne Lumsden, Ph.D.
Senior Scientific Program Manager, Drug Development Partnership Programs
National Center for Advancing Translational Sciences, NIH
Cat Lutz, Ph.D.
Senior Director, Mouse Repository & In Vivo Pharmacology, Rare and Orphan Disease Center
The Jackson Laboratory
Stephen Mason, Ph.D.
Research Associate & Viral Drug Discovery Fellow
Pfizer
Frank Nestle, M.D.
Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America
Sanofi
Elizabeth Ottinger, Ph.D.
Senior Program Manager, Division of Preclinical Innovation
National Center for Advancing Translational Sciences, NIH
David Payne, Ph.D.
Vice President & Head, Medicine Opportunities Research Unit
GlaxoSmithKline
Louise Pitt, Ph.D.
Director, Center for Aerobiological Sciences
U.S. Army Medical Research Institute of Infectious Diseases